Featured Research

from universities, journals, and other organizations

Novel regulatory process for T cells may help explain immune system diseases

Date:
October 19, 2010
Source:
Cincinnati Children's Hospital Medical Center
Summary:
A newly identified regulatory process affecting the biology of immune system T cells should give scientists new approaches to explore the causes of autoimmunity and immune deficiency diseases. Scientists report a novel process of coordinated cellular communications vital to the maintenance of T cells. If the process breaks down, T cells proliferate rapidly and die off. This could disrupt the immune system's normal defensive functions.

A newly identified regulatory process affecting the biology of immune system T cells should give scientists new approaches to explore the causes of autoimmunity and immune deficiency diseases.

In findings posted online ahead of publication in Proceedings of the National Academy of Sciences (PNAS), scientists at Cincinnati Children's Hospital Medical Center report a novel process of coordinated cellular communications vital to the maintenance of T cells. If the process breaks down, T cells proliferate rapidly and die off. This could disrupt the immune system's normal defensive functions.

"This study involves an important mechanistic finding affecting the molecular regulation of T cell biology that will have implications in our future understanding of immunodeficiency and autoimmunity," said Yi Zheng, Ph.D., co-investigator on the study and director of Experimental Hematology/Cancer Biology at Cincinnati Children's.

T cells -- named such because they originate in the thymus -- are a type of white blood cell vital to the body's immune system and its defense against pathogens and disease.

Scientists entered the current study knowing from earlier research that normal T cell biology involves carefully coordinated signaling between what are known as T cell receptors and a gene/protein called interluken-7 receptor (IL-7Ra). IL-7Ra is vital to the formation of white blood cells called lymphocytes, which include T cells. Unknown before this study, however, were the detailed mechanisms that regulate this coordination.

In a variety of test tube experiments and experiments involving mice, researchers determined the cell division control protein Cdc42 is essential to coordinating a signaling network of genes/proteins and enzymes that control normal T cell biology. The disruption caused by loss of Cdc42 included restricted signaling by IL-7Ra, an initial hyper-proliferation of T cells and their rapid loss through programmed cell death. When the researchers were able to reconstitute Cdc42 in their experiments, T cell biology became more normalized, they report.

The study was led by Fukun Guo, Ph.D., in the division of Experimental Hematology/Cancer Biology at Cincinnati Children's. The scientists plan to follow up their study by looking for additional details about the molecular pathways affected through Cdc42's central regulatory role in T cell biology. They also want to look for Cdc42's potential application to new diagnostic or therapeutic approaches for diseases affecting the immune system.

Funding support came from the National Institutes of Health and a Cincinnati Children's Trustee grant.


Story Source:

The above story is based on materials provided by Cincinnati Children's Hospital Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. F. Guo, D. Hildeman, P. Tripathi, C. S. Velu, H. L. Grimes, Y. Zheng. Coordination of IL-7 receptor and T-cell receptor signaling by cell-division cycle 42 in T-cell homeostasis. Proceedings of the National Academy of Sciences, 2010; DOI: 10.1073/pnas.1010249107

Cite This Page:

Cincinnati Children's Hospital Medical Center. "Novel regulatory process for T cells may help explain immune system diseases." ScienceDaily. ScienceDaily, 19 October 2010. <www.sciencedaily.com/releases/2010/10/101019111705.htm>.
Cincinnati Children's Hospital Medical Center. (2010, October 19). Novel regulatory process for T cells may help explain immune system diseases. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/10/101019111705.htm
Cincinnati Children's Hospital Medical Center. "Novel regulatory process for T cells may help explain immune system diseases." ScienceDaily. www.sciencedaily.com/releases/2010/10/101019111705.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins